Home > Insider Trading > Filing (0001415889-25-018309)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1534133	Calcimedica Inc.	CALC	Pharmaceutical Preparations (2834)	452120079

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1942596	Stephen Bardin	C/O Calcimedica, Inc. 505 Coast S. Blvd, #307 La Jolla CA 92037	Chief Financial Officer	No	No	No	No

Transaction Summary

Purchased:	2,000 shares	Avg. Price: $1.50	Total Value: $3,005.00
Number of Shares After Transactions:	3,000 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-06-26	2,000	$1.50	3,000	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2025-06-24	20,000	$0.00	20,000	$1.53

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,000		2035-04-22	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	40,000	Direct

Footnotes

The weighted average purchase price for the transaction reported was $1.5025, and the range of prices were between $1.45 and $1.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Includes 1,000 shares held by The Bardin Family Trust dated June 4, 2024 (the "Trust") which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025.
By The Bardin Family Trust dated June 4, 2024.
Excludes 1,000 shares held by the Trust which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025.
The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.
Immediately exercisable.